Home » Archive by Category

News

San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.

Essentialis To Present Clinical Update At The

November 14, 2014 – 5:00 am | Edit Post

CARLSBAD, Calif., Nov. 14, 2014 /PRNewswire/ –Essentialis announced today that Dr. Neil M. Cowen, President and Chief Scientific Officer, will be presenting a summary of interim results of clinical study PC025 on November 16, 2014 at the Annual Research…

Tocagen Inc. Appoints As Chairman Of The Board Of Directors

November 14, 2014 – 5:00 am | Edit Post

SAN DIEGO, Nov. 14, 2014 /PRNewswire/ –Tocagen Inc., a clinical-stage selective cancer immunotherapy company, today announced that Faheem Hasnain, president and chief executive officer of Receptos, Inc. (Nasdaq…

Aethlon Medical’s Hemopurifier?? Used In Successful Treatment Of Patient With Advanced Ebola Infection

November 14, 2014 – 5:00 am | Edit Post

SAN DIEGOandPHILADELPHIA, Nov. 14, 2014 /PRNewswire/ — The Aethlon Hemopurifier was used in the successful treatment of a critically-ill Ebola-infected patient in Frankfurt, Germany, according to data presented today at the

Signal Genetics LLC Provides Overview Of Recent Corporate Achievements

November 14, 2014 – 5:00 am | Edit Post

CARLSBAD, Calif., Nov. 14, 2014 (GLOBE NEWSWIRE) — Signal Genetics, Inc. (Nasdaq:SGNL) (Signal), a commercial stage, molecular diagnostic company focused on providing innovative diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from…

Thermo Fisher Scientific Release: New Digital PCR Application Identifies Drug Metabolizing Phenotypes

November 14, 2014 – 5:00 am | Edit Post

CARLSBAD, Calif.–(BUSINESS WIRE)–A new digital PCR (dPCR) application for the QuantStudio 3D Digital PCR System enables researchers to accurately phenotype the CYP2D6 gene, a key indicator of drug metabolism. Thermo Fisher Scientific announced the new application, which enhances its extensive offering in the pharmacogenomics (PGx) field, during the 2014 Association for Molecular Pathology conference…

Dermtech Withdraws $25 Million IPO

November 14, 2014 – 5:00 am | Edit Post

DermTech, which is developing non-invasive gene expression tests to diagnosis various skin conditions, withdrew its plans for an initial public offering on Thursday citing poor market conditions.Skin-related biotech IPO Dermira (DERM) raised $125 million in October by pricing at the high end of the range, and now trades about 1.5% above the offer price.The La Jolla, CA-based…

Biocept, Inc. Reports Third Quarter 2014 Financial Results

November 14, 2014 – 5:00 am | Edit Post

SAN DIEGO, Nov. 13, 2014 (GLOBE NEWSWIRE) — Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in Circulating Tumor Cells (CTCs) and Circulating Tumor DNA (ctDNA) biomarker analysis, today announced its financial results for the third quarter ended September 30, 20…

Celladon Corporation Selected To Present During The “Best Of Circulation Research” Symposium At The American Heart Association Scientific Sessions 2014

November 14, 2014 – 5:00 am | Edit Post

SAN DIEGO, Nov. 14, 2014 (GLOBE NEWSWIRE) — Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company with industry-leading expertise in the development of cardiovascular gene therapy, today announced that Krisztina Zsebo, Ph.D., Chief Executive Officer of Celladon, was selected to…

Isis Pharmaceuticals, Inc. To Present At Upcoming Investor Conferences

November 14, 2014 – 5:00 am | Edit Post

CARLSBAD, Calif., Nov. 14, 2014 /PRNewswire/ — Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at:Stifel 2014 Healthcare Conference on Wednesday, November 19, 2014<…

Pfenex Inc. Reports Q3 Revenue of $2.8 Million

November 13, 2014 – 6:30 pm | Edit Post

Pfenex Inc., a clinical-stage biotechnology company that makes biosimilars, including vaccines for anthrax and malaria, reported financial results for the third quarter that ended Sept. 30, 2014.